2.15

2.27% -0.05

After Hours: 2.15

Oramed Pharmaceuticals Inc (ORMP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Oramed Pharmaceuticals Inc stock is traded at $2.15, with a volume of 113.17K. It is down -2.27% in the last 24 hours and down -2.27% over the past month. Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Previous Close:

$2.20

Open:

$2.2

24h Volume:

113.17K

Relative Volume:

0.99

Market Cap:

$87.83M

Revenue:

$2.70M

Net Income/Loss:

$5.53M

P/E Ratio:

19.55

EPS:

0.11

Net Cash Flow:

$-10.55M

1W Performance:

-4.44%

1M Performance:

-2.27%

6M Performance:

-3.59%

1Y Performance:

-7.73%

1-Day Range:

$2.09

$2.29

1-Week Range:

$2.09

$2.35

52-Week Range:

$1.82

$3.09

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name

Oramed Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

646-844-1164

Address

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY

Employee

Twitter

@OramedPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

ORMP's Discussions on Twitter

Compare ORMP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORMP Oramed Pharmaceuticals Inc	2.15	91.91M	2.70M	5.53M	-10.55M	0.11
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight
Apr-20-21	Initiated	Canaccord Genuity	Buy
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy
Mar-11-20	Initiated	Aegis Capital	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy
May-26-16	Reiterated	FBR Capital	Outperform
Dec-01-15	Reiterated	H.C. Wainwright	Buy
Nov-19-15	Initiated	FBR Capital	Outperform
Apr-13-15	Resumed	MLV & Co	Buy
Jan-30-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Initiated	MLV & Co	Buy
Dec-03-13	Initiated	Aegis Capital	Buy

View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

May 15, 2025

Oramed: Q1 Earnings Snapshot - MySA

May 15, 2025

May 13, 2025

Alpha Tau Medical appoints new board member By Investing.com - Investing.com India

May 13, 2025

May 12, 2025

Alpha Tau Medical appoints new board member - Investing.com

May 12, 2025

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire

May 12, 2025

Apr 29, 2025

Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize

Apr 29, 2025

Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus

Apr 29, 2025

Apr 28, 2025

Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com

Apr 28, 2025

Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq

Apr 28, 2025

Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical - marketscreener.com

Apr 28, 2025

Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire

Apr 28, 2025

Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation - Stock Titan

Apr 28, 2025

Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz

Apr 28, 2025

Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan

Apr 28, 2025

Apr 25, 2025

Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa

Apr 09, 2025

Mar 27, 2025